About

Dr. Melanie Tan is a pioneering urologic surgeon and researcher whose work is transforming the surgical management of bladder cancer. Her primary research focuses on optimizing outcomes for patients undergoing radical cystectomy, with a particular emphasis on comparing robot-assisted techniques—specifically those with intracorporeal urinary diversion—against traditional open surgery. Dr. Tan’s landmark contribution is the iROC trial, a randomized controlled trial that demonstrated the superiority of robot-assisted radical cystectomy in reducing 90-day morbidity and mortality, a finding published in 2022 that has already garnered over 320 citations and reshaped clinical guidelines. She has also been instrumental in integrating enhanced recovery after surgery (ERAS) protocols with robotic approaches, showing that this combination can significantly shorten hospital stays and improve perioperative outcomes. Her work extends to health economics, where she has shown that robot-assisted surgery is cost-effective for healthcare payers. With a cumulative citation count exceeding 550, Dr. Tan is a leading voice in evidence-based surgical innovation, and her research continues to set the standard for safer, more efficient bladder cancer care.

Research Focus

Key Achievements

6
H-Index
10
Papers
568
Total Citations
57
Avg Citations/Paper
🏆 Most Cited Paper
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer
320 citations · 2022
📈 Most Prolific Year: 2017 (3 Papers)
🤝 Key Collaborators: 102
🏛 Institutions: Society of Interventional Radiology, Peter MacCallum Cancer Centre, University College London, University College Hospital, University College Hospital at Westmoreland Street, Age UK

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago